Editorial: Targeting gastric cancer with trastuzumab: New clinical practice and innovative developments to overcome resistance

Annals of Surgical Oncology

Volumn 17, Issue 1, 2010, Pages 14-17

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ADENOCARCINOMA; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; EPIDEMIOLOGICAL DATA; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL ADENOCARCINOMA; GASTROINTESTINAL CARCINOMA; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH SURGERY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG RESISTANCE; IMMUNOLOGY; STOMACH TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 74649083025     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0766-0     Document Type: Editorial

References (10)

1. HJ Burstein 2005 The distinctive nature of HER2-positive breast cancers N Engl J Med 353 16 1652 1654 10.1056/NEJMp058197 1:CAS:528:DC%2BD2MXhtFahsLjM 16236735 (Pubitemid 41464703)
2. A Gschwind OM Fischer A Ullrich 2004 The discovery of receptor tyrosine kinases: targets for cancer therapy Nat Rev Cancer 4 5 361 370 10.1038/nrc1360 1:CAS:528:DC%2BD2cXjsFSlu7g%3D 15122207 (Pubitemid 38579482)
3. J Baselga SM Swain 2009 Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 Nat Rev Cancer 9 7 463 475 10.1038/nrc2656 1:CAS:528:DC%2BD1MXnsVagtbs%3D 19536107
4. C Gravalos A Jimeno 2008 HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 19 9 1523 1529 10.1093/annonc/mdn169 1:STN:280:DC%2BD1crivFajtQ%3D%3D 18441328
5. E Van Cutsem Y Kang H Chung, et al. 2009 Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) J Clin Oncol 27 18s 10.1200/JCO.2009.22.4626 suppl; abstr LBA4509
6. P Bastiaens 2009 Systems biology: when it is time to die Nature 459 7245 334 335 10.1038/459334a 1:CAS:528:DC%2BD1MXmtFKmtb0%3D 19458703
7. S Jones X Zhang DW Parsons 2008 Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 5897 1801 1806 10.1126/science.1164368 1:CAS:528:DC%2BD1cXhtFCrtLrL 18772397
8. DH Roukos 2009 Personalized cancer diagnostics and therapeutics Expert Rev Mol Diagn 9 3 227 229 10.1586/erm.09.6 19379081
9. TS Diestock 2009 Personalizing medicine: a systems biology perspective Mol Syst Biol. 5 249
10. DH Roukos 2009 Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine Expert Rev Mol Diagn 9 3 217 221 10.1586/erm.09.7 19379079